Cargando…
Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
BACKGROUND: Bevacizumab (Avastin(®)), a monoclonal antibody targeting vascular endothelial growth factor (VEGF)-A, is widely used in treating a variety of malignant tumors. Several biosimilars of bevacizumab have been developed and marketed with the expiration of bevacizumab’s patent. The objective...
Autores principales: | Xiao, Xian, Zhang, Guixing, Sun, Binxu, Wang, Chaoran, Wang, Xiaoqun, Kong, Fanming, Jia, Yingjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273685/ https://www.ncbi.nlm.nih.gov/pubmed/35836506 http://dx.doi.org/10.21037/tcr-22-71 |
Ejemplares similares
-
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)
por: Syrigos, Konstantinos, et al.
Publicado: (2021) -
Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021) -
Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study
por: Zhao, Zhiting, et al.
Publicado: (2023) -
Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) in patients with advanced non-squamous non-small cell lung cancer
por: Li, Cheryl S. W., et al.
Publicado: (2019) -
Long Noncoding RNA: Shining Stars in the Immune Microenvironment of Gastric Cancer
por: Xiao, Xian, et al.
Publicado: (2022)